![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.biospectrumasia.com/news/25/24475/japan-approves-first-post-transplant-anti-cytomegalovirus-infection-treatment.html
https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf
https://www.europeanpharmaceuticalreview.com/news/176332/first-oral-therapy-approved-post-transplant-refractory-cmv/
https://www.takeda.com/newsroom/newsreleases/2022/european-commission-ec-approves-livtencitytm-maribavir/
https://www.clinicaltrialsarena.com/news/takeda-cmv-livtencity-trial/
https://www.clinicaltrialsarena.com/news/takeda-cmv-livtencity-trial/
https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-cell-gene-therapy-deals-bms-beigene-abraxane-brawl
https://endpts.com/fdas-antimicrobial-adcomm-unanimously-backs-takedas-drug-for-post-transplant-cytomegalovirus/
https://pharmaphorum.com/news/fda-panel-backs-takedas-cmv-drug-for-transplant-patients/
https://www.healthcarefinancenews.com/news/hrsa-orders-boehringer-ingelheim-comply-340b-drug-pricing
https://endpts.com/fda-offers-support-for-takedas-potential-cytomegalovirus-drug-ahead-of-adcomm/
https://www.fiercebiotech.com/biotech/takeda-s-maribavir-clears-cytomegalovirus-infections-phase-3
https://www.takeda.com/newsroom/newsreleases/2020/new-phase-3-data-show-tak-620-maribavir-an-investigational-drug-for-the-treatment-of-transplant-recipients-with-refractoryresistant-cytomegalovirus-cmv-infections-meets-primary-endpoint/
https://www.businesswire.com/news/home/20190924005143/en/New-England-Journal-Medicine-Publishes-Results-Phase/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://endpts.com/top-10-takedas-late-stage-pipeline-will-rely-heavily-on-shire-drugs-but-is-it-worth-62b/